文献速递血栓与止血浆细胞疾病

阿哌沙班用于多发性骨髓瘤患者接受免疫调节药物时静脉血栓栓塞的一级预防

Primary prevention of venous thromboembolism with apixaban for multiple myeloma patients receiving immunomodulatory agents.
PubMed 文献 · Br J Haematol · 2020-04-21

6个月内无大出血或症状性VTE发生,3例出现临床相关非大出血且经内科处理后可恢复用药,1例因过敏停药。低剂量阿哌沙班安全且耐受良好,但需进一步研究验证其作为标准预防策略。

要点

  • 3例发生临床相关非大出血,均可经内科处理并恢复阿哌沙班。
  • 1例因阿哌沙班过敏早期停药,未见卒中、心梗或死亡。

核心结论

  • 低剂量阿哌沙班作为接受IMiDs的MM患者VTE一级预防安全且耐受良好。
  • 需进一步研究验证低剂量阿哌沙班作为标准一级预防抗血栓策略。

研究设计与样本

  • 主要安全结局为6个月内大出血和临床相关非大出血发生率,主要疗效结局为6个月内症状性VTE发生率。

主要发现

  • 6个月评估期内无患者发生大出血或VTE。
  • 3例发生临床相关非大出血,经内科处理,均能恢复阿哌沙班。
  • 1例因对阿哌沙班过敏在开始后不久停药。
  • 无患者发生卒中、心肌梗死或死亡。
  • 使用的IMiDs为来那度胺(58%)或泊马度胺(42%)。

关键数值与推荐

  • IMiDs使用情况:来那度胺58%,泊马度胺42%。

临床怎么用

  • 对于接受IMiDs的MM患者,可考虑低剂量阿哌沙班作为VTE一级预防。
  • 用药期间需监测出血事件,临床相关非大出血经处理后可恢复用药。
  • 过敏反应是停药原因之一,需注意识别。

局限性

  • 单臂试点研究,无对照组。
  • 需进一步研究验证低剂量阿哌沙班作为标准预防策略。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Immunomodulatory drugs (IMiDs) have improved survival of patients with multiple myeloma (MM) and comprise the therapeutic backbone at all phases of therapy. Although well-tolerated, IMiDs increase rates of venous thromboembolism (VTE). In this phase IV, single-arm pilot study, fifty patients with MM on IMiDs received apixaban 2·5 mg orally twice daily for primary prevention of VTE and were prospectively monitored for six months. The primary safety outcomes were rates of major haemorrhage and clinically relevant non-major haemorrhage over six months. The primary efficacy outcome was the rate of symptomatic VTE over six months. IMiDs used were lenalidomide (58%) or pomalidomide (42%). During the six-month evaluation period, no patients experienced major haemorrhage or VTE. Three patients experienced clinically relevant, non-major haemorrhage which was managed medically, and all were able to resume apixaban. One patient stopped therapy shortly after initiation due to an allergic reaction to apixaban. No patients experienced stroke, myocardial infarction, or death. In this pilot study, low-dose apixaban was safe and well-tolerated as a primary prevention therapy of VTE for patients with MM receiving IMiDs. Further studies are needed to validate low-dose apixaban as a standard primary prevention anti-thrombotic strategy for patients with MM receiving IMiDs.

来源:Br J Haematol,查看原文。版权归原作者所有。

引用

  1. Cornell RF, Goldhaber SZ, Engelhardt BG, et al. Primary prevention of venous thromboembolism with apixaban for multiple myeloma patients receiving immunomodulatory agents. Br J Haematol. 2020. PMID: 32314352. doi:10.1111/bjh.16653

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。